SGT 501
Alternative Names: SGT-501Latest Information Update: 08 Sep 2025
At a glance
- Originator Solid Biosciences
- Class Antiarrhythmics; Gene therapies
- Mechanism of Action CASQ2 protein replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Polymorphic catecholergic ventricular tachycardia
Most Recent Events
- 08 Sep 2025 Solid Biosciences plans the first-in-human phase Ib ARTEMIS trial for Polymorphic catecholergic ventricular tachycardia (In children, In adolescents, In adults, In the elderly) in USA (IV, Infusion), in October 2025 (NCT07148089),
- 23 Jul 2025 SGT 501 receives Fast Track designation for Polymorphic catecholergic ventricular tachycardia [Parenteral] in USA
- 08 Jul 2025 US FDA and Health Canada approves IND and CTA application, respectively for SGT 501 in Polymorphic catecholergic ventricular tachycardia